Condition: Cardiotoxicity · Anthracycline-induced Cardiotoxicity · Sponsor: Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
The goal of the trial is the early detection of cardiotoxicity in patients treated with anthracycline-based chemotherapy. Current diagnostics, such as troponin T, NT-pro-BNP, electrocardiogram, and echocardiography, are not able to identify early myocardial damage. Therefore, this study aims to identify early myocardial damage by using cardiac magnetic resonance imaging. The primary endpoint of this study is the change in relaxation times in CMR before, during, and after therapy. Furthermore, the study analyzes: * other abnormal results in CMR * changes in troponin T and NT-pro-BNP * changes in global longitudinal strain in echocardiography and correlation with results of CMR * detection of new biomarkers in blood, urine, or stool
This description comes directly from the study's public registry record.
Matthias Prof. Dr. med. Schwab · 0049 + 0711-8101 3700 · matthias-schwab@ikp-stuttgart.de
Always discuss trial participation with your own doctor first.
| Robert Bosch Gesellschaft für Medizinische Forschung mbH | Stuttgart, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07528586